-- Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 -- -- Maintaining 2025 Revenue Guidance -- -- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and Achievement of 20%+ Revenue CAGR -- MOUNTAIN VIEW, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported that as part of a strategic refocusing of its product portfoli ...

MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 24th Annual Needham Virtual Healthcare Conference at 3:00pm ET (12:00pm PT) on Tuesday, April 8, 2025. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for 90 ...

NeuroPace, Inc. (NASDAQ:NPCE) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Joel Becker - Chief Executive Officer and Board Member Rebecca Kuhn - Chief Financial Officer, Vice President, Finance and Administration Conference Call Participants Priya Sachdeva - UBS Rohin Patel - JP Morgan Frank Takkinen - Lake Street Capital Markets Mike Kratky - Leerink Partners Vik Chopra - Wells Fargo Matthew Park - Cantor Fitzgerald Michael Pollard - Wolf ...

Financial Data and Key Metrics Changes - Total revenue for 2024 increased by 22% to $79.9 million compared to $65.4 million in 2023, with record quarterly revenue reported in Q4 [10][31] - Q4 2024 revenue was $21.5 million, representing a 19% growth compared to $18 million in Q4 2023, driven primarily by increased sales of the RNS system [30][31] - Gross margins for Q4 2024 were 75.4%, slightly up from 75.2% in Q4 2023, with improvements attributed to increased RNS product sales [31][34] Business Line Data and Key Metrics Changes - RNS system sales grew by 27% in Q4 2024, excluding contributions from Nautilus study cases in Q4 2023 [30] - Revenue from Dixie Medical products accounted for approximately 17% of total revenue in 2024, up from 15% in 2023 [31] Market Data and Key Metrics Changes - The core market opportunity within level four comprehensive epilepsy centers is estimated at approximately $2 billion annually [12] - The Project CARE initiative has begun to show positive trends, with increased implants and referrals contributing to revenue growth in the second half of 2024 [13][14] Company Strategy and Development Direction - The company’s growth strategy focuses on expanding adoption within level four comprehensive epilepsy centers, enhancing service delivery through Project CARE, and broadening indications for the RNS system [11] - Key development programs include ongoing clinical studies for idiopathic generalized epilepsy and pediatric focal epilepsy, with positive safety and effectiveness data expected to support regulatory approvals [15][17][20] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a revenue growth rate of over 20% annually over the next three years while aiming for cash flow breakeven [41] - The company anticipates total revenue for 2025 to be in the range of $92 million to $96 million, representing a 15% to 20% increase over 2024 [37] Other Important Information - The company completed a public offering that raised approximately $69.8 million, with $49.5 million used to repurchase shares from an early investor [35][26] - The cash and short-term investments balance as of February 28, 2025, is approximately $68.6 million, expected to support operations until achieving cash flow breakeven [36] Q&A Session Summary Question: Guidance for 2025 - Management discussed factors influencing revenue guidance, including execution of the three-part strategy and expansion of Project CARE [44][45] Question: Impact of Project CARE - Management noted meaningful impacts from Project CARE, with increased referrals and implants observed in Q4 [48] Question: Capital Prioritization - Management emphasized investment in expanding adoption within level four centers and direct-to-consumer efforts as key priorities for 2025 [52][54] Question: Gross Margin Trends - Management highlighted ongoing volume increases and pricing opportunities as primary drivers for gross margin improvement [58][61] Question: Indication Expansion and Reimbursement - Management confirmed established reimbursement for current indications and plans to work with payers to expand coverage for new indications [66] Question: Revenue Cadence for 2025 - Management expects a steady progression of growth throughout the year, similar to previous years [70] Question: Multiple Implants from New Accounts - Management confirmed seeing multiple implants and referrals from new accounts, indicating strong economic viability for RNS outside level four centers [75][76] Question: Pediatric Treatment Dynamics - Management explained that pediatric treatment dynamics would be similar to adult patients, focusing on the type of epilepsy rather than age [96] Question: Manufacturing Capacity - Management stated that manufacturing capacity is sufficient to meet anticipated demand [99] Question: Nautilus Study Data Presentation - Management plans to coordinate the publication and presentation of Nautilus data with relevant agencies and societies [105][108]

Part I [Item 1. Business](index=8&type=section&id=Item%201.%20Business) NeuroPace develops the RNS System, a brain-responsive neuromodulation device for drug-resistant focal epilepsy, aiming to expand market adoption, indications, and leverage brain data - The company's core product is the RNS System, the first and only commercially available brain-responsive neuromodulation system for drug-resistant focal epilepsy, with over **6,000 patients treated** as of December 31, 2024[21](index=21&type=chunk) - The RNS System is currently indicated for adults with drug-resistant focal epilepsy, representing an estimated **$27 billion total addressable market** in the U.S., with indication expansion pursued for generalized epilepsy and pediatric patients[23](index=23&type=chunk) - Recent real-world data demonstrates improving efficacy, with a median seizure frequency reduction of **82% at three or more years**, superior to original pivotal study results[30](index=30&type=chunk)[58](index=58&type=chunk) - In August 2022, NeuroPace became the exclusive U.S. distributor for DIXI Medical's Stereo EEG product line, providing an incremental revenue stream and earlier visibility into potential RNS System candidates[101](index=101&type=chunk) [Our RNS System](index=12&type=section&id=Our%20RNS%20System) The RNS System is a closed-loop neuromodulation device that continuously monitors brain activity and delivers personalized electrical stimulation to prevent seizures, leveraging extensive patient data - The RNS System's implantable components include a neurostimulator placed in the skull and leads with electrodes on or within the brain, which sense electrical activity and provide targeted stimulation[43](index=43&type=chunk) - The system includes external components like the Patient Remote Monitor for data upload and a Physician Tablet for programming and reviewing iEEG data, supported by the PDMS secure online database and the nSight Platform for patient reports and programming suggestions[47](index=47&type=chunk)[48](index=48&type=chunk)[49](index=49&type=chunk)[50](index=50&type=chunk)[51](index=51&type=chunk) - As of December 31, 2024, the system has generated an extensive database of over **nineteen million iEEG records** from more than **6,000 patients**, which is leveraged to improve clinical outcomes[52](index=52&type=chunk) - The current RNS System model has an average battery life of nearly **eleven years**, an increase from the previous model, with over **90% of patients** choosing a replacement in 2019 when their device reached end-of-life[57](index=57&type=chunk) [Clinical Data and Studies](index=16&type=section&id=Clinical%20Data%20and%20Studies) Clinical studies demonstrate the RNS System's efficacy, with a 75% median seizure reduction at nine years and 82% at 36 months, with ongoing studies for label expansion - The Long-Term Treatment (LTT) study, following patients for nine years, demonstrated a median seizure frequency reduction that improved from **44% at one year to 75% at nine years**[84](index=84&type=chunk)[85](index=85&type=chunk)[86](index=86&type=chunk) - The recent Post-Approval Study showed even better real-world outcomes, with an **82.0% median seizure reduction at 36 months** post-implant[92](index=92&type=chunk) - The company is conducting two key label expansion studies: the RESPONSE study for adolescents (ages 12-17) with focal epilepsy and the NAUTILUS study for patients with idiopathic generalized epilepsy (IGE), for which the RNS System received FDA Breakthrough Device Designation[93](index=93&type=chunk)[94](index=94&type=chunk) [Commercial Strategy and Collaborations](index=20&type=section&id=Commercial%20Strategy%20and%20Collaborations) NeuroPace employs a direct sales force, expanding its prescriber base beyond Level 4 CECs, and collaborates with DIXI Medical and Rapport Therapeutics for distribution and data leverage - A 2023 PMA-S approval expanded the potential prescriber base from Level 4 CECs to an additional **1,800 epileptologists** and the entire population of functional neurosurgeons in the community[96](index=96&type=chunk) - The company has an exclusive distribution agreement with DIXI Medical for its Stereo EEG product line in the U.S., which is synergistic as it provides earlier access to patients in epilepsy monitoring units, with the initial three-year term expiring September 30, 2025[101](index=101&type=chunk) - A collaboration with Rapport Therapeutics leverages the RNS System's data and biomarker monitoring capabilities to evaluate a product candidate in Rapport's Phase 2a clinical trial[102](index=102&type=chunk) [Manufacturing and Supply](index=26&type=section&id=Manufacturing%20and%20Supply) NeuroPace manufactures its RNS System in a 53,000 sq ft FDA-compliant facility in California, relying on single-source suppliers for critical components - All manufacturing and distribution occurs at the company's facility in Mountain View, California, which is FDA registered and compliant with QSR[130](index=130&type=chunk)[133](index=133&type=chunk) - The company relies on single-source suppliers for key components, including printed circuit assemblies from Micro Systems Technologies Management AG and batteries from Greatbatch Ltd[135](index=135&type=chunk) - NeuroPace has participated in the FDA Voluntary Improvement Program for **seven years**, which involves annual on-site appraisals and quarterly check-ins in lieu of routine FDA facility inspections[134](index=134&type=chunk) [Government Regulation](index=27&type=section&id=Government%20Regulation) The RNS System is a Class III medical device subject to stringent FDA regulations, healthcare fraud and abuse laws, and data privacy compliance - The RNS System is a **Class III medical device**, requiring the most stringent FDA review pathway, the Premarket Approval (PMA) application, which was originally approved in 2013[32](index=32&type=chunk)[144](index=144&type=chunk) - The company's operations are subject to numerous healthcare fraud and abuse laws, such as the federal Anti-Kickback Statute, the False Claims Act, and the Physician Payments Sunshine Act, which regulate interactions with healthcare professionals[166](index=166&type=chunk)[168](index=168&type=chunk)[173](index=173&type=chunk)[176](index=176&type=chunk) - The company must adhere to data privacy and security laws, including HIPAA and HITECH, which govern the handling of protected health information (PHI), with failure to comply resulting in significant civil and criminal penalties[191](index=191&type=chunk)[192](index=192&type=chunk) [Human Capital Resources](index=37&type=section&id=Human%20Capital%20Resources) As of December 31, 2024, NeuroPace had 184 U.S.-based employees, emphasizing retention and a value-driven culture, with 45% having five or more years of tenure - As of December 31, 2024, the company had **184 employees**, all located in the U.S., with none represented by a labor union[196](index=196&type=chunk) - The company highlights strong employee retention, with **45% of its workforce** (83 employees) having been with NeuroPace for at least five years[200](index=200&type=chunk) [Item 1A. Risk Factors](index=40&type=section&id=Item%201A.%20Risk%20Factors) The company faces risks from RNS System market acceptance, single-source supplier dependence, intense competition, complex reimbursement, regulatory hurdles, and a history of net losses - The company's business depends primarily on the RNS System, which is only marketed in the U.S. for adults with drug-resistant focal epilepsy, and failure to expand market share and adoption will negatively affect sales[208](index=208&type=chunk) - NeuroPace depends on a limited number of single-source suppliers for critical components like printed circuit assemblies and batteries, making it vulnerable to supply shortages and price fluctuations[223](index=223&type=chunk) - The company competes with larger, well-capitalized companies like LivaNova (VNS System) and Medtronic (DBS System), which have more established sales programs and broader resources[233](index=233&type=chunk)[234](index=234&type=chunk)[235](index=235&type=chunk) - The company has a history of net losses (**$27.1 million in 2024**, **$33.0 million in 2023**) and an accumulated deficit of **$531.0 million** as of year-end 2024, and expects to incur losses for the foreseeable future[395](index=395&type=chunk) - The existing Term Loan Agreement contains restrictive covenants, including minimum annual revenue and liquidity requirements, which if breached, could lead to an event of default and immediate repayment[397](index=397&type=chunk) [Item 1B. Unresolved Staff Comments](index=92&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company has no unresolved staff comments from the SEC - None[462](index=462&type=chunk) [Item 1C. Cybersecurity](index=93&type=section&id=Item%201C.%20Cybersecurity) NeuroPace manages cybersecurity risks through an information security program, overseen by its Privacy and Security Officer and audit committee, involving threat assessment, mitigation, and vendor management - The company's cybersecurity risk management is overseen by the Privacy and Security Officer and the board of directors' audit committee[471](index=471&type=chunk)[472](index=472&type=chunk) - The risk management strategy includes monitoring the threat environment, conducting vulnerability scans, penetration testing, and engaging third-party experts to identify and assess threats[464](index=464&type=chunk)[467](index=467&type=chunk) - A vendor management program is in place to manage cybersecurity risks from third-party providers, involving security questionnaires, risk assessments, and contractual obligations[468](index=468&type=chunk) [Item 2. Properties](index=94&type=section&id=Item%202.%20Properties) The company leases a 53,000 sq ft facility in Mountain View, California, for its headquarters and manufacturing, with the lease expiring in 2030 - The company's headquarters and manufacturing facility is a leased **53,000 sq. ft.** space in Mountain View, CA, with the lease expiring in **2030**[476](index=476&type=chunk) [Item 3. Legal Proceedings](index=94&type=section&id=Item%203.%20Legal%20Proceedings) The company is not currently involved in any legal proceedings expected to have a material adverse effect on its business - The company is not currently involved in any material legal proceedings[672](index=672&type=chunk) [Item 4. Mine Safety Disclosures](index=94&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - None[478](index=478&type=chunk) Part II [Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=95&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) NeuroPace's common stock trades on Nasdaq under "NPCE" since April 2021, with no anticipated dividends, and $92.7 million of IPO proceeds used for general corporate purposes - The company's common stock trades on the Nasdaq under the symbol **"NPCE"** since April 22, 2021[481](index=481&type=chunk) - The company does not plan to pay cash dividends in the foreseeable future[483](index=483&type=chunk) - From the April 2021 IPO, which raised **$105.5 million** in net proceeds, approximately **$92.7 million** has been used for general corporate purposes as of December 31, 2024[486](index=486&type=chunk) [Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=96&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) FY2024 revenue grew 22% to $79.9 million, net loss narrowed to $27.1 million, with $52.8 million in cash, supplemented by a $69.8 million follow-on offering Results of Operations (FY 2024 vs. FY 2023) | | Years Ended December 31, | | | | | :--- | :--- | :--- | :--- | :--- | | **(in thousands)** | **2024** | **2023** | **$ Change** | **% Change** | | Revenue | $79,906 | $65,421 | $14,485 | 22% | | Gross Profit | $59,085 | $48,122 | $10,963 | 23% | | *Gross Margin* | *73.9%* | *73.6%* | | | | Total Operating Expenses | $80,756 | $75,296 | $5,460 | 7% | | Loss from Operations | $(21,671) | $(27,174) | $5,503 | (20)% | | Net Loss | $(27,141) | $(32,956) | $5,815 | (18)% | - Revenue growth of **22% in FY2024** was driven by an increase in RNS System units sold and higher sales of DIXI Medical products, which accounted for **17% of total revenue**[523](index=523&type=chunk) - As of December 31, 2024, the company had **$52.8 million** in cash, cash equivalents, and short-term investments, and **$59.5 million** in outstanding debt, which management believes is sufficient to fund operations for at least the next 12 months[494](index=494&type=chunk)[496](index=496&type=chunk) - In February 2025, the company raised approximately **$69.8 million** in net proceeds from a follow-on offering, using **$49.5 million** to repurchase all shares held by significant stockholder KCK Ltd[531](index=531&type=chunk) [Item 7A. Quantitative and Qualitative Disclosures About Market Risk](index=106&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate sensitivity on its $52.8 million cash and investments, with no material impact expected from a 10% rate change - The company's main market risk is interest rate sensitivity on its **$52.8 million** of cash, cash equivalents, and short-term investments[557](index=557&type=chunk) - Due to the short-term and low-risk nature of its investments, the company does not expect a **10% change in interest rates** to have a material impact on the fair value of its financial instruments[557](index=557&type=chunk) [Item 8. Financial Statements and Supplementary Data](index=107&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the company's audited financial statements for 2024 and 2023, including an unqualified opinion from PricewaterhouseCoopers LLP - The independent auditor, PricewaterhouseCoopers LLP, issued an **unqualified (clean) opinion** on the financial statements, stating they present fairly, in all material respects, the financial position of the company[566](index=566&type=chunk) Key Balance Sheet Data (as of Dec 31, 2024) | Account | Amount (in thousands) | | :--- | :--- | | **Assets** | | | Cash, cash equivalents & short-term investments | $52,755 | | Total Current Assets | $81,339 | | Total Assets | $94,647 | | **Liabilities & Equity** | | | Total Current Liabilities | $15,156 | | Long-term debt | $59,525 | | Total Liabilities | $86,634 | | Total Stockholders' Equity | $8,013 | Key Statement of Operations Data (Year ended Dec 31, 2024) | Account | Amount (in thousands) | | :--- | :--- | | Revenue | $79,906 | | Gross Profit | $59,085 | | Total Operating Expenses | $80,756 | | Net Loss | $(27,141) | | Net Loss Per Share | $(0.93) | [Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=136&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports no changes or disagreements with its accountants on accounting and financial disclosure - None[733](index=733&type=chunk) [Item 9A. Controls and Procedures](index=136&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2024, with no material changes - Management concluded that the company's disclosure controls and procedures were **effective** as of December 31, 2024[734](index=734&type=chunk) - Management concluded that the company's internal control over financial reporting was **effective** as of December 31, 2024[737](index=737&type=chunk) - The report does not include an auditor's attestation on internal controls, as the company is exempt as an emerging growth company[738](index=738&type=chunk) [Item 9B. Other Information](index=136&type=section&id=Item%209B.%20Other%20Information) No directors or officers adopted, modified, or terminated Rule 10b5-1 trading plans during Q4 2024 - No directors or officers adopted, modified, or terminated any Rule 10b5-1 trading plans during the quarter ended December 31, 2024[739](index=739&type=chunk) Part III [Item 10. Directors, Executive Officers and Corporate Governance](index=137&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information on directors, executive officers, and corporate governance is incorporated by reference from the 2025 Proxy Statement - Information is incorporated by reference from the 2025 Proxy Statement[743](index=743&type=chunk) [Item 11. Executive Compensation](index=138&type=section&id=Item%2011.%20Executive%20Compensation) Information on executive and director compensation is incorporated by reference from the 2025 Proxy Statement - Information is incorporated by reference from the 2025 Proxy Statement[746](index=746&type=chunk) [Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=138&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Information on security ownership and equity compensation plans is incorporated by reference from the 2025 Proxy Statement - Information is incorporated by reference from the 2025 Proxy Statement[747](index=747&type=chunk) [Item 13. Certain Relationships and Related Transactions, and Director Independence](index=138&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information on related party transactions and director independence is incorporated by reference from the 2025 Proxy Statement - Information is incorporated by reference from the 2025 Proxy Statement[748](index=748&type=chunk) [Item 14. Principal Accountant Fees and Services](index=138&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Information on principal accountant fees and services is incorporated by reference from the 2025 Proxy Statement - Information is incorporated by reference from the 2025 Proxy Statement[749](index=749&type=chunk) Part IV [Item 15. Exhibit and Financial Statement Schedules](index=139&type=section&id=Item%2015.%20Exhibit%20and%20Financial%20Statement%20Schedules) This section lists the financial statements and exhibits filed with the Annual Report on Form 10-K - This item lists the financial statements and exhibits filed with the 10-K[752](index=752&type=chunk)[754](index=754&type=chunk) [Item 16. Form 10–K Summary](index=143&type=section&id=Item%2016.%20Form%2010%E2%80%93K%20Summary) The company indicates no Form 10-K summary - None[763](index=763&type=chunk)

Investor Presentation March 2025 1 Joel Becker Chief Executive Officer Martha Morrell, MD Chief Medical Officer Rebecca Kuhn Chief Financial Officer Kelley Nicholas Vice President, Sales Previous Experience *Recent additions to leadership team in Research and Development, Marketing and Human Resources 4 Disclaimer This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by ...

-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net proceeds to repurchase 100% of KCK holdings and $20.2 million to strengthen its balance sheet to support planned operations to reach cash flow breakeven -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, ...

Company Overview - NeuroPace, Inc. is a commercial-stage medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy by reducing or eliminating debilitating seizures [3] - The company’s RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source, aiming to improve care for patients with drug-resistant epilepsy [3] Upcoming Events - NeuroPace's management team will present at the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, at 4:20pm ET in Miami, FL, and will also host investor meetings during the conference [1] - The presentation will be accessible via live webcast, with a replay available for two weeks following the event on NeuroPace's Investor website [2]

Company Overview - NeuroPace, Inc. is a commercial-stage medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy by reducing or eliminating debilitating seizures [3] - The company has developed the RNS System, which is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source [3] - The RNS System aims to improve the standard of care for patients with drug-resistant epilepsy and has potential applications for other brain disorders [3] Upcoming Events - NeuroPace's management team will present at the Leerink Partners 2025 Global Healthcare Conference on January 10, 2025, at 4:20 PM ET in Miami, FL [1] - The presentation will be accessible via live webcast, with a replay available for two weeks following the event on NeuroPace's Investor website [2]

Company Overview - NeuroPace, Inc. (NPCE) shares increased by 5.8% to $14.23 in the last trading session, following a higher-than-average trading volume, contrasting with a 4.2% loss over the past four weeks [1] - The company is set to release its fourth-quarter 2024 financial results on March 4, 2025, after the market closes [2] Financial Performance Expectations - The Zacks Consensus Estimate anticipates a revenue growth of 19.2% for the fourth quarter, projecting revenues of $21.46 million compared to the same quarter last year [2] - The expected quarterly loss is $0.25 per share, reflecting an 8.7% decrease year-over-year [2] Earnings Estimate Trends - The consensus EPS estimate for NeuroPace has remained unchanged over the last 30 days, indicating a lack of upward revisions which typically correlate with stock price movements [4] - The stock's recent price increase may not sustain without a trend in earnings estimate revisions, suggesting the need for close monitoring of NPCE's performance [4] Industry Context - NeuroPace operates within the Zacks Medical - Instruments industry, where Tandem Diabetes Care, Inc. (TNDM) also resides, having closed 1.3% higher at $32.12, but with a -9.4% return over the past month [4] - Tandem Diabetes Care's consensus EPS estimate has remained unchanged at -$0.21, representing a 22.2% increase compared to the previous year's EPS [5]